⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL746498 | 1.00 | — | — | |
| SCHEMBL18562098 | 0.71 | — | — | |
| SCHEMBL30684769 | 0.71 | — | — | |
| SCHEMBL29472011 | 0.71 | — | — | |
| SCHEMBL906218 | 0.71 | — | — | |
| SCHEMBL18576652 | 0.67 | — | — | |
| SCHEMBL13619082 | 0.67 | — | — | |
| SCHEMBL7079561 | 0.66 | — | — | |
| SCHEMBL5849008 | 0.66 | ALDH1A1 (0.46) | — | |
| SCHEMBL218726 | 0.62 | ALDH1A1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504763-A | Nitrogen-enriched condensed ring energetic compound and preparation method thereof | 西南科技大学 | 2025-02-25 | — | — | CN | claimed |
| CN-122055156-A | (R) -N-ethyl-5-fluoro-N-isopropyl-2- ((5- (2- (6- ((2-methoxyethyl) (methyl) amino) -2-methyl-hex-3-yl) -2, 6-diazaspiro [3.4] oct-6-yl) -1,2, 4-triazin-6-yl) oxy) benzamide, formulations and dosing regimens for treating cancer | 詹森药业有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-119504763-B | Nitrogen-enriched condensed ring energetic compound and preparation method thereof | 西南科技大学 | 2025-11-07 | — | — | CN | disclosed |
| EP-4581032-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2025-07-09 | — | — | EP | disclosed |
| CN-117658936-B | Synthesis method of 3,5, 6-trichloro- [1,2,4] -triazine | 上海予君生物科技发展有限公司 | 2025-06-06 | — | — | CN | disclosed |
| CN-117658936-B | Synthesis method of 3,5, 6-trichloro- [1,2,4] -triazine | 上海予君生物科技发展有限公司 | 2025-06-06 | — | — | CN | disclosed |
| WO-2025082444-A2 | (R) -N-ETHYL-5-FLUORO-N-ISOPROPYL-2- ( (5- (2- (6- ( (2-METHOXYETHYL) (METHYL) AMINO) -2-METHYLHEXAN-3-YL) -2, 6-DIAZASPIRO [3.4] OCTAN-6-YL) -1, 2, 4-TRIAZIN-6-YL) OXY) BENZAMIDE, FORMULATIONS AND DOSAGE REGIMENS THEREOF, FOR USE IN TREATING CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-24 | — | — | WO | disclosed |
| CN-119562950-A | Novel pyrimidinyl and triazinyl sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119504763-A | Nitrogen-enriched condensed ring energetic compound and preparation method thereof | 西南科技大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-119504763-A | Nitrogen-enriched condensed ring energetic compound and preparation method thereof | 西南科技大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-116159449-A | Method for preparing reverse osmosis membrane and reverse osmosis membrane prepared by same | 沃顿科技股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| WO-2022262796-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-M ETHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT FOR THE TREATMENT OF DISEASES SUCH AS CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237627-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022241265-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237720-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237626-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| EP-4077312-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867721-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114315796-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-04-12 | — | — | CN | disclosed |